This page shows the publications co-authored by Donna Neuberg and Maureen Achebe.
Sudden death in sickle cell disease: current experience. Br J Haematol. 2020 02; 188(4):e43-e45.
Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea. Blood. 2015 Jun 04; 125(23):3668-9.
Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson. Blood. 2013 Apr 25; 121(17):3329-34.
Sickle cell disease (SCD), iNKT cells, and regadenoson infusion. Trans Am Clin Climatol Assoc. 2012; 123:312-7; discussion 317-8.
Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease. Blood Adv. 2017 Sep 12; 1(20):1645-1649.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.